| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692910 | Contraception | 2016 | 25 Pages |
Abstract
Due to its favourable bleeding pattern and cycle control, the 15 mg E4/DRSP combination is the preferred combination for further phase III clinical development.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Dan Apter, Yvette Zimmerman, Louise Beekman, Marie Mawet, Catherine Maillard, Jean-Michel Foidart, Herjan J.T. Coelingh Bennink,